{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:25:35Z","timestamp":1794338735152,"version":"4.9.0"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers\n(ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists\n(MRA) reduce mortality and hospitalizations in heart failure with reduced ejection fraction (HFrEF) but\ntheir use is limited in advanced chronic kidney disease (CKD).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We carried out a systematic review of studies on HFrEF and CKD patients. The mean overall\npercentage of reported ACEI, ARB, MRA, and ARNI use, and the proportion of trials that included\npatients with advanced CKD grades 4-5 (estimated glomerular filtration rate (eGFR) &lt;15-30\nml\/min\/1.73m2) were recorded per year. The proportion of trials with advanced CKD was logtransformed,\nand then fitted into a time regression model. The interactions between the proportion of\ntrials that included CKD grades 4-5 and the proportion of reported use of ACEI, ARB, and MRAs per\nyear were explored using Pearson\u2019s correlation and univariate linear regression.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 706 articles were included; 76% reported background ACEI\/ARB use, while 51%\nreported MRA use. ACEI\/ARB use averaged 83% and MRA 50%. Of the trials, 57% included CKD\ngrades 4-5. Over 10 years, the proportion of trials with CKD grades 4-5 increased while ACEI\/ARB use\ndecreased. MRA use rates remained about the same. There was an inverse association found between\nthe proportion of trials with CKD grades 4-5 and ACEI\/ARB use per year.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In the past 10 years, CKD grades 4-5 patients have been increasingly included in HFrEF\nclinical trials. Concurrently, ACEI\/ARB use has reportedly decreased.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161121666230314114549","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:29:42Z","timestamp":1678858182000},"page":"106-110","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u201cRenalism\u201d with Renin Angiotensin Aldosterone System Inhibitor Use in\nPatients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction\nand Advanced Chronic Kidney Disease: A Systematic Review"],"prefix":"10.2174","volume":"21","author":[{"given":"Hussein Al","family":"Sudani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Einstein Medical Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Einstein Medical Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Bryan","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Einstein Medical Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Essa","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"},{"name":"Liverpool Centre for Cardiovascular Science, Liverpool Heart &amp; Chest Hospital, Liverpool, UK"},{"name":"Department of Cardiology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammaar","family":"Wattoo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Einstein Medical Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Angelim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Einstein Medical Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Brousas","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Whybrow-Huppatz","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaitalya","family":"Vellanki","sequence":"additional","affiliation":[{"name":"School of Medicine, George\nWashington University Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Sankaranarayanan","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"},{"name":"Liverpool Centre for Cardiovascular Science, Liverpool Heart &amp; Chest Hospital, Liverpool, UK"},{"name":"Department of Cardiology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Rangaswami","sequence":"additional","affiliation":[{"name":"School of Medicine, George\nWashington University Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox T.M.","year":"2021","unstructured":"Maddox T.M.; Januzzi J.L.; Allen L.A.; 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol 2021,77(6),772-810","journal-title":"J Am Coll Cardiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","volume":"78","author":"Patel R.B.","year":"2021","unstructured":"Patel R.B.; Fonarow G.C.; Greene S.J.; Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 2021,78(4),330-343","journal-title":"J Am Coll Cardiol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","year":"2021","unstructured":"Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021,99(3S),S1-S87","journal-title":"Kidney Int"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"101047","DOI":"10.1016\/j.cpcardiol.2021.101047","author":"Lo K.B.","year":"2021","unstructured":"Lo K.B.; Essa H.; Wattoo A.; Representation of chronic kidney disease in randomized controlled trials among patients with heart failure with reduced ejection fraction: A systematic review. Curr Probl Cardiol 2021,101047","journal-title":"Curr Probl Cardiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/jcm11082243","volume":"11","author":"Beltrami M.","year":"2022","unstructured":"Beltrami M.; Milli M.; Dei L.L.; Palazzuoli A.; The treatment of heart failure in patients with chronic kidney disease: Doubts and new developments from the last ESC guidelines. J Clin Med 2022,11(8),2243","journal-title":"J Clin Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1681\/ASN.2018070674","volume":"29","author":"Maini R.","year":"2018","unstructured":"Maini R.; Wong D.B.; Addison D.; Chiang E.; Weisbord S.D.; Jneid H.; Persistent underrepresentation of kidney disease in randomized, controlled trials of cardiovascular disease in the contemporary era. J Am Soc Nephrol 2018,29(12),2782-2786","journal-title":"J Am Soc Nephrol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/ckj\/sfab290","volume":"15","author":"Ortiz A.","year":"2022","unstructured":"Ortiz A.; Navarro-Gonz\u00e1lez J.F.; N\u00fa\u00f1ez J.; The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure. Clin Kidney J 2022,15(5),865-872","journal-title":"Clin Kidney J"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00041552-200403000-00004","volume":"13","author":"Silverberg D.","year":"2004","unstructured":"Silverberg D.; Wexler D.; Blum M.; Schwartz D.; Iaina A.; The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004,13(2),163-170","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/kisup.2012.64","volume":"3","year":"2013","unstructured":"Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011) 2013,3(1),19-62","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fcell.2020.00185","volume":"8","author":"Carracedo J.","year":"2020","unstructured":"Carracedo J.; Alique M.; Vida C.; Mechanisms of cardiovascular disorders in patients with chronic kidney disease: A process related to accelerated senescence. Front Cell Dev Biol 2020,8,185","journal-title":"Front Cell Dev Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/CIRCHEARTFAILURE.111.966242","volume":"5","author":"McAlister F.A.","year":"2012","unstructured":"McAlister F.A.; Ezekowitz J.; Tarantini L.; Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 2012,5(3),309-314","journal-title":"Circ Heart Fail"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"Damman K.","year":"2014","unstructured":"Damman K.; Valente M.A.E.; Voors A.A.; O\u2019Connor C.M.; van Veldhuisen D.J.; Hillege H.L.; Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014,35(7),455-469","journal-title":"Eur Heart J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jchf.2019.02.009","volume":"7","author":"Hein A.M.","year":"2019","unstructured":"Hein A.M.; Scialla J.J.; Edmonston D.; Cooper L.B.; DeVore A.D.; Mentz R.J.; Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. JACC Heart Fail 2019,7(5),371-382","journal-title":"JACC Heart Fail"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2215\/CJN.14180920","volume":"16","author":"Banerjee D.","year":"2021","unstructured":"Banerjee D.; Rosano G.; Herzog C.A.; Management of heart failure patient with CKD. Clin J Am Soc Nephrol 2021,16(7),1131-1139","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.7150\/ijms.55119","volume":"18","author":"Chen Y.L.","year":"2021","unstructured":"Chen Y.L.; Hang C.L.; Su C.H.; Feature and impact of guideline-directed medication prescriptions for heart failure with reduced ejection fraction accompanied by chronic kidney disease. Int J Med Sci 2021,18(12),2570-2580","journal-title":"Int J Med Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.amjms.2017.11.008","volume":"355","author":"Cutshall B.T.","year":"2018","unstructured":"Cutshall B.T.; Duhart B.T.; Saikumar J.; Samarin M.; Hutchison L.; Hudson J.Q.; Assessing guideline-directed medication therapy for heart failure in end-stage renal disease. Am J Med Sci 2018,355(3),247-251","journal-title":"Am J Med Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ahj.2007.03.017","volume":"153","author":"Berger A.K.","year":"2007","unstructured":"Berger A.K.; Duval S.; Manske C.; Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007,153(6),1064-1073","journal-title":"Am Heart J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/01.CIR.0000138934.28340.ED","volume":"110","author":"Masoudi F.A.","year":"2004","unstructured":"Masoudi F.A.; Rathore S.S.; Wang Y.; National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004,110(6),724-731","journal-title":"Circulation"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","year":"1987","unstructured":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med CONSENSUS Trial Study Group1987,316(23),1429-1435","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1016\/0002-9149(93)90951-8","volume":"71","author":"Riegger G.A.J.","year":"1993","unstructured":"Riegger G.A.J.; Lessons from recent randomized controlled trials for the management of congestive heart failure. Am J Cardiol 1993,71(17),E38-E40","journal-title":"Am J Cardiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"Granger C.B.","year":"2003","unstructured":"Granger C.B.; McMurray J.J.V.; Yusuf S.; Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003,362(9386),772-776","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.7326\/ACPJC-2004-140-2-032","volume":"140","author":"Pitt B.","year":"2004","unstructured":"Pitt B.; Candesartan reduced mortality and hospital admissions in chronic heart failure. ACP J Club 2004,140(2),32-33","journal-title":"ACP J Club"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1097\/01.ASN.0000135969.33773.0B","volume":"15","author":"Chertow G.M.","year":"2004","unstructured":"Chertow G.M.; Normand S.L.; McNeil B.J.; \u201cRenalism\u201d: Inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol 2004,15(9),2462-2468","journal-title":"J Am Soc Nephrol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ahj.2016.03.024","volume":"178","author":"Fr\u00f6hlich H.","year":"2016","unstructured":"Fr\u00f6hlich H.; Nelges C.; T\u00e4ger T.; Long-term changes of renal function in relation to ace inhibitor\/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Am Heart J 2016,178,28-36","journal-title":"Am Heart J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000457946","volume":"137","author":"Kane J.A.","year":"2017","unstructured":"Kane J.A.; Kim J.K.; Haidry S.A.; Salciccioli L.; Lazar J.; Discontinuation\/dose reduction of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers during acute decompensated heart failure in african-american patients with reduced left-ventricular ejection fraction. Cardiology 2017,137(2),121-125","journal-title":"Cardiology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.cjco.2022.06.007","volume":"4","author":"Barry A.R.","year":"2022","unstructured":"Barry A.R.; Managing heart failure with reduced ejection fraction in patients with chronic kidney disease: A case-based approach and contemporary review. CJC Open 2022,4(9),802-809","journal-title":"CJC Open"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","volume":"18","author":"van der Aart-van der Beek A.B.","year":"2022","unstructured":"van der Aart-van der Beek A.B.; de Boer R.A.; Heerspink H.J.L.; Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 2022,18(5),294-306","journal-title":"Nat Rev Nephrol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"082","DOI":"10.31083\/j.rcm2303082","volume":"23","author":"Lioudaki E","year":"2022","unstructured":"Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E; The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys. Rev Cardiovasc Med 2022,23(3),082","journal-title":"Rev Cardiovasc Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ehf2.12265","volume":"5","author":"Pitt B.","year":"2018","unstructured":"Pitt B.; Bushinsky D.A.; Kitzman D.W.; Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 2018,5(3),257-266","journal-title":"ESC Heart Fail"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"Pitt B.","year":"2015","unstructured":"Pitt B.; Bakris G.L.; Bushinsky D.A.; Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015,17(10),1057-1065","journal-title":"Eur J Heart Fail"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-021-01555-5","volume":"81","author":"Valdivielso J.M.","year":"2021","unstructured":"Valdivielso J.M.; Balafa O.; Ekart R.; Hyperkalemia in chronic kidney disease in the new era of kidney protection therapies. Drugs 2021,81(13),1467-1489","journal-title":"Drugs"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jacc.2012.12.022","volume":"61","author":"Banka G.","year":"2013","unstructured":"Banka G.; Heidenreich P.A.; Fonarow G.C.; Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. J Am Coll Cardiol 2013,61(13),1440-1446","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161121666230314114549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/214612\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161121666230314114549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T18:36:59Z","timestamp":1691865419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/214612\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161121666230314114549","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"0022-11-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}